BUZZ-Pharvaris jumps as oral therapy for genetic disorder meets main goal in late-stage trial** Shares of oral therapy developer Pharvaris PHVS.O rise 11.9% to $27 premarket
** Co's oral therapy, Deucrictibant, for on-demand treatment of hereditary angioedema $(HAE)$ attacks meets primary endpoint
** HAE attacks are sudden episodes of severe swelling in different parts of the body caused by a genetic disorder
** PHVS says the treatment demonstrated faster treatment response and symptom relief compared to placebo
** Co says it remains on track to submit the new drug application with the U.S. FDA in the first half of 2026
** PHVS up 25.8% YTD, up to last close
(Reporting by Utkarsh Tushar Hathi in Bengaluru)
((utkarshtushar.hathi@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments